Alnylam third quarter income boosts from $24.

Paul is the former President of the Lilly Analysis Laboratories of Eli Lilly and Company. Alnylam also announced the pension of James L. Vincent from Alnylam’s Board of Directors. Mr. Vincent may be the former Chief Executive Chairman and Officer of Biogen Idec, Inc. Expanded Alnylam Biotherapeutics Scientific Advisory Board. Alnylam announced today that Alnylam Biotherapeutics extended its Scientific Advisory Plank with the appointment of Randal Kaufman, Ph.D. Dr. Kaufman can be Professor of Biological Chemistry and Internal Medication at the University of Michigan Medical School.. Alnylam third quarter income boosts from $24.2 million to $27.7 million Alnylam Pharmaceuticals, Inc. , a leading RNAi therapeutics company, reported its consolidated financial outcomes for the third quarter ended September 30 today, 2010, and firm highlights.Cerner, Baxa indication strategic reseller agreement for DoseEdge Pharmacy Workflow Manager Cerner Corporation and Baxa Corporation have got signed a strategic reseller contract for the Baxa DoseEdge Pharmacy Workflow Manager. The contract enables Cerner to market and resell the Baxa DoseEdge System as part of a Cerner offering. Cerner clients now have usage of a broader suite of solutions and accredited integration for dose tracking from compounding to delivery. ‘The contract expands our offering and positions Cerner to continue increasing interoperability across the medication procedure,’ says Tom Herzog, Cerner vice president, IT and medical gadget technologies.